

---

# Index

---

**Accessorial liability**

infringement of a patent by authorisation, 5-17, 146-166

**Apple Inc**

trademarks for the design and layout of retail premises, 167-185

**Audio-visual media – see Broadcast media****Australian Law Reform Commission Inquiry into Copyright and the Digital Economy**

exception for fair use recommended by, 129-145

fair use and the digital economy, 218-234

final report of, 192-193

on retransmission, 202-217

**Australia-United States Free Trade Agreement (AUSFTA)**

infringement by authorisation and, 15

minimum standard system for “other use of the subject matter of a patent without authorisation”, 96-97, 99-100

**Biotechnological innovation**

the generally inconvenient exception, 40-58

patentability of human embryonic stem cells and, 18-39

**Book reviews**

Code Wars – 10 Years of P2P Software Litigation by Rebecca Giblin, 186-188

**Brand protection strategies**

trademarks for the design and layout of retail premises, 167-185

**Broadcast media**

retransmission in, 202-217

**Brüstle v Greenpeace eV**

patentability of human embryonic stem cells and, 18-39

**Canada**

law of fair dealing in, 137-144

**Cancer Voices Australia v Myriad Genetics Inc**

case study, value neutrality within patent law, 45-47

**Competition**

American shop rights doctrine and the inventions of Australian employees, 109-124

biotechnology patents in Australia, 40-58

**Compulsory licensing**

affordability of patented drugs and, 94-108

policy justifications for, 103-104

**Contributory infringement – see Infringement by authorisation****Convergence Review, 202, 212-216**

---

## Index

---

### **Copyright**

authorisation as accessory liability – *see Infringement by authorisation*  
Code Wars – 10 Years of P2P Software Litigation book review, 186-188  
fair use exception – *see Fair use*  
fairness and balance: lessons from Canada, 129-145  
iiNet case, privacy in context of piracy, 59-69  
impact of fair dealing provisions on innovation, 220-223  
retransmission of broadcasts and, 202-217  
universalism in, 206-208

### **Copyright Act 1968 (Cth)**

ALRC inquiry recommends fair use exception, 129-145  
goals of, 219  
s 101(1A), privacy and, 63-64, 66-67

### **Copyright Act 1976 (US)**

on fair use, 193  
market effect provisions, 199-200

### **Crown use – *see Government (Crown) use***

### **Cultural policies**

retransmission of broadcasts and, 202-217

### **Design of retail premises**

trademarks for, 167-185  
distinctiveness, 178-181  
use as a trade mark, 172-178, 181-184

### **Designs Act 2003 (Cth) and Designs Regulations**

patent attorney work under, 88-90

### **Digital economy**

fair use and, 218-234

### **DNA or RNA sequences – *see Gene structures, isolated***

### **Drug affordability – *see Pharmaceuticals***

### **Embryonic stem cells – *see Human embryonic stem cells***

### **Employees**

shop rights doctrine and inventions of, 109-124

### **Equitable estoppel**

doctrinal basis of the shop right and, 114-115, 122

### **Equity and fairness**

doctrinal basis of the shop right and, 117

### **Ethics**

ethical exclusion against patentability, 18-39, 40-58

ethical objections and normative theory, 47-50  
Federal Court's role as ethical guardian, 52-57  
morality exclusion in European patent law, 18-19  
parliamentary inertia regarding, 50-52  
patentability of human embryonic stem cells and, 18-39  
patentability of isolated DNA or RNA sequences, 47-50

**Europe**

EPO on patentability of biotechnological innovations, 55-57  
patentability of human embryonic stem cells, 18-39

**Fair dealing**

Canadian law, 137-144  
fair use proposals and, 129-145, 220-223, 231-234  
rationales for, 132-134

**Fair use**

current fair dealing provisions and, 220-223, 231-234  
digital economy and, 218-234  
impact on innovation in the US, 223-227  
legislative reforms from Fair Use Review, 219  
recommendations for, and possible interpretations of, 129-145  
US legislation relating to, 192-201

**Federal Court**

role as ethical guardian, 52-57

**Gene structures, isolated**

patentability of, 45-47

**General third party non-voluntary licensing**

affordability of patented drugs and, 97-101

**“Generally inconvenient” proviso**

biotechnology patents in Australia, 40-58  
“reasonable person” test amendment of, 57

**Giblin, Rebecca**

Code Wars – 10 Years of P2P Software Litigation book review, 186-188

**Government (Crown) use**

compulsory licensing and drug affordability, 101-102

**Government acquisition**

compulsory licensing and drug affordability, 102

**Human embryonic stem cells**

creation of chimeric embryos, 34-36  
ethical objections to patents and, 48-49

---

## **Index**

method and medium for in vitro culture of, 30-33, 36  
patentability of, 18-39

**Human genes – see Gene structures, isolated**

**iiNet case**

privacy in context of piracy and, 59-69

**Implied authorisation – see Accessorial liability**

**Implied licence**

doctrinal basis of the shop right and, 115-117, 122

**In vitro fertilisation – see Luminis, Re**

**Infringement by authorisation**

as accessorial liability

the overlooked role of knowledge, 146-166

defined, 149-151

examples of, 152-159

express request, direction cases, 152-153

internet cases, 157-159

live performance on premises, 155-156

providing mechanical means of copying, 153-155

factors to consider, 159-161

knowledge, 161-166

nature of any relationship, 160

power to prevent; control, 160

reasonable steps to prevent the doing of an act, 161

infringement of a patent by authorisation, 5-17

background to the introduction of, 6-11

international dimensions, 15-16

scope under patent law, 7-10

**Infringement of trade marks**

design of retail premises, 181-184

substantial identity and deceptive similarity, 183-184

**Innovation – see also Biotechnological innovation**

American shop rights doctrine and the inventions of Australian employees, 109-124

impact of fair dealing provisions on, 220-223

**Intellectual property – see Copyright; Infringement by authorisation; Patents; Trade marks**

**Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)**

biotechnology patents: raising the bar on the generally inconvenient exception, 40-58

**Internet Service Providers (ISPs)**

iiNet case, privacy in context of piracy and, 59-69

**Invention – see Innovation**

**Ireland**

proposed fair use model in, 231

**“Joint tortfeasors” – see Accessorial liability**

**Knowledge**

authorisation as accessorial liability and, 146-166

**Layout of retail premises**

trademarks for design and, 167-185

**Legal practice**

“engage in legal practice”

giving legal advice, 78-80

holding oneself out as an “attorney” or “lawyer”, 82

legal practice and trademarks and designs work, 82-83

meaning of, 75-77, 82-84, 86-87, 92

providing assistance with legal documents, 81

representation before a tribunal with the power to make legally binding decisions, 78

exclusive right to engage in conferred on solicitors and barristers, 74-93

prohibition on engaging in, and its application to PTAs, 74-93

enabling Commonwealth legislation, 85-91

**Legal Profession National Law and the Legal Profession National Rules**

position of PTAs under, 83-85

the “safe harbour”, 83

use of the title “attorney”, 84

working with lawyers under the proposed national law, 84

prohibition on engaging in legal practice and its application to patent and trademarks attorneys, 74-93

**Liability, accessorial – see Accessorial liability**

**Licences**

based on shop rights doctrine – see **Shop rights doctrine**

compulsory – see **Compulsory licensing**

**Luminis, Re**

invention for the method and medium for in vitro culture of human embryos, 30-33, 36

**Market effect provisions**

in US copyright cases, 199-200

**Media policy**

retransmission of broadcasts, 202-217

**Monopoly position**

“generally inconvenient” proviso derived from s 6 of the Statute of Monopolies 1623

ethical exclusion against patentability, 40-58

---

## Index

---

**Morality – see Ethics**

**“Must carry” obligation**

for broadcasters, 209

**Non-voluntary licensing**

affordability of patented drugs and, 97-101

**Normative theory**

ethical objections to patents and, 47-50

**Online copyright piracy**

iiNet case, privacy in context of piracy and, 59-69

**“Ordre public”**

concept of in objections to patents, 55

**P2P software**

Code Wars – 10 Years of P2P Software Litigation book review, 65-66

**Patent and trademarks attorneys (PTAs)**

application of prohibition on engaging in legal practice to, 74-93

enabling Commonwealth legislation, 85-91

reference to provisions dealing with professional privilege, 90-91

under the Designs Act and Regulations, 88-90

under the Patents Act and Regulations, 85-87

under the Trade Marks Act and Regulations, 87-88

**Patents**

accessing and affording drugs despite the patent barrier, 94-108

controversial biotechnology patents, 40-58

ethical patent law exclusion, 18-39

infringement by authorisation, 5-17

patentability of human embryonic stem cells in Australia and Europe, 18-39

raising the bar on the generally inconvenient exception, 40-58

“work” the invention, defined, 99

**Patents Act 1990 (Cth)**

compulsory licences, 94-108

patent and trademarks attorneys under, 85-87

ss 13(1) and 117, infringement of a patent by authorisation, 5-17

origins of authorisation in, 11-13

s 18(1), “generally inconvenient” proviso derived from s 6 of the Statute of Monopolies 1623, 40-58

s 18(2), patentability of human embryonic stem cells and Brüstle v Greenpeace eV, 18-39

**Peer-to-peer (communication and copying) technologies**

Code Wars – 10 Years of P2P Software Litigation book review, 186-188

**Personal information**

privacy in context of piracy and, 65-66

**Pharmaceuticals**

accessing and affording drugs despite the patent barrier, 94-108

**Piracy – see Copyright**

**Privacy**

in the context of piracy, 59-69

**Professional privilege**, 90-91

defining the scope of PTA practice by reference to the provisions dealing with, 90-91

**“Reasonable person” test**

derived from “generally inconvenient” proviso, 57

**Reproduction**

embryonic stem cells – *see Human embryonic stem cells*

**Rescare judgment**

infringement by authorisation and, 7-8, 17

**Retail premises**

trademarks for the design and layout of, 167-185

**Retransmission of broadcasts**, 202-217

**“Secondary” liability in the law of copyright – *see Infringement by authorisation***

**Shop rights doctrine**

overview, 110-114

doctrinal basis of, 114-118

American shop rights doctrine, 109-124

defences, 117-118

employee inventions in Australia, 119-124

Spencer Industries Pty Ltd v Collins, 122-123

University of Western Australia v Gray, 121-122

Victoria University of Technology v Wilson, 119-121

**Shops – *see Retail premises***

**Software**

Code Wars – 10 Years of P2P Software Litigation book review, 186-188

**Statute of Monopolies 1623**

“generally inconvenient” proviso derived from s 6 of, 40-58

**Stem cells – *see Human embryonic stem cells***

**Therapeutics – *see Biotechnological innovation***

**Third party non-voluntary licensing**

affordability of patented drugs and, 97-101

---

## **Index**

### **Trade Marks Act and Trade Marks Regulations**

patent attorney work under the under, 87-88

### **Trademarks – *see also Patent and trademarks attorneys***

for the design and layout of retail premises, 167-185

trade mark infringement, 181-184

trade dress, 168-171

### **Transformative use**

fair use legislation and, 195-199

### **TRIPS Agreement**

ethical exclusion against patentability and, 51

infringement by authorisation and, 15

minimum requirements, 96-97

right of member states to “flexibly” apply compulsory licensing, 94-108

scope of Art 27(2) of regarding patentability exclusion, 40-58

### **Two Pesos Inc v Taco Cabana Inc**

trade dress, 169-170

### **Two-step fair use test**

benefits of, 233-234

### **United Kingdom**

fair use provisions, 223

infringement by authorisation and, 15-16

### **United States**

copyright law, 218

fair use legislation in, 192-201, 223-227

infringement by authorisation and, 15-16

### **Value neutrality within patent law, 43-47**

biotechnology patents in Australia, 40-58

Cancer Voices Australia: A case study, 45-47

inappropriateness of ethical discussion in patent law, 45

utilitarian justification for granting patents

utilitarian objective, 44-45

### **Woo-Suk Hwang case**

creation of chimeric embryos, 34-36

### **“Work” the invention**

defined, 99